Ultraclav
Presentation:
Ultraclav 625 Tablet: Each film coated tablet contains Amoxycillin Trihydrate BP equivalent to Amoxycillin 500 mg and Potassium Clavulanate USP equivalent to Clavulanic Acid 125 mg.
Description
Ultraclav (beta-lactam antibacterial penicillin co-formulated with a beta-lactamase inhibitor) is an antibiotic agent with a notably broad spectrum of activity against the commonly occurring bacterial pathogens in general practice and hospital. The beta-lactamase inhibitory action of clavulanate extends the spectrum of amoxicillin to embrace a wider range of organisms, including many resistant to other beta-lactam antibiotics. Amoxicillin is a semi synthetic antibiotic with a broad spectrum of antibacterial activity against many gram-positive and gram-negative micro-organisms. Amoxicillin is, however susceptible to degradation by beta-lactamases and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate a wide range of beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. The presence of clavulanic acid in Ultraclav formulations protects amoxicillin from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other penicillins and cephalosporins. Thus Ultraclav possesses the distinctive properties of a broad spectrum antibiotic and a beta-lactamase inhibitor.
Therapeutic Class: Broad-spectrum penicillin + β-lactamase inhibitor.
